Studies on the human monocytic leukaemia cell line THP-1 with NPM1 mutation reveal an increase in sensitivity to chemotherapy drugs through suppressing NF-κB activity and BCL-2/BAX expression, which is pertinent to the efficacy of venetoclax seen in NPM1-mutated AML [131]. Here, NPM1 is linked to monocytic leukemia.